An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the vaccine candidate appeared to be safe and produced a clear immune response in all nine patients at high risk for recurrences of their cancer.

A new vaccine for kidney cancer shows excellent preliminary results. All patients on the trial had no evidence of cancer three years after the pioneering treatment.

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, researchers report.

In a Phase 1 study, nine people with advanced kidney cancer became cancer free after receiving personalized vaccines.

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful anti-cancer immune response after initiation of a personalized cancer vaccine.

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated robust immune response, according to findings of a new study led by HMS researchers at Dana-Farber Cancer Institute.

A cancer vaccine generated using the cells left over after tumour removal surgery could help to keep patients from redeveloping cancer.

Groundbreaking personalized kidney cancer vaccines show promise in early clinical trials, triggering strong immune responses and keeping patients cancer-free for years.